Recent interest has sparked for neoadjuvant systemic therapy with immune checkpoint inhibitors.

Last, we outline the role of emerging neoadjuvant approaches, which may complement adjuvant strategies and are currently investigated in clinical trials.

The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.

Patients with muscle-invasive bladder cancer who are current or former smokers are more likely to respond poorly to cisplatin-based neoadjuvant chemotherapy than their nonsmoking counterparts, researchers report in BJU International .

Patients with borderline resectable or locally advanced pancreatic cancer experience a significant loss of adipose tissue along with an increase in muscle mass during neoadjuvant therapy that may improve the odds for resection, researchers report.

Receiving neoadjuvant plus adjuvant dabrafenib and trametinib significantly improves event-free survival compared with standard care in patients with high-risk melanoma, phase II study findings indicate.

Patients with locally advanced rectal cancer who receive total neoadjuvant therapy are more likely to adhere to chemotherapy and to experience a complete response than those treated with preoperative chemoradiation followed by postoperative adjuvant chemotherapy, according to the findings of a retrospective cohort analysis.

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

Men are less likely than women to achieve a pathologic complete response to neoadjuvant chemotherapy for invasive, nonmetastatic breast cancer, US researchers report.

After completing neoadjuvant therapy, 82.1% of the 397 patients in the pembrolizumab arm underwent planned surgery, as did 79.4% of the 400 patients given placebo.

Phase 2 data point to the promising efficacy of adding ipilimumab to neoadjuvant nivolumab plus chemotherapy in people with operable non-small-cell lung cancer.

Cohort 3 – patients have progression or recurrence following platinum chemotherapy for metastatic disease or within 12 months of neoadjuvant or adjuvant chemotherapy.

Results from the phase 2 NEOBLADE trial show no significant improvement in the rate of pathologic complete response among patients with locally advanced muscle-invasive bladder cancer who receive the multikinase inhibitor nintedanib alongside standard neoadjuvant chemotherapy.

The addition of the oncolytic virus talimogene laherparepvec to neoadjuvant chemotherapy may increase responses in women with nonmetastatic triple-negative breast cancer, say phase 2 trial investigators.

A phase 2 trial has demonstrated the promising efficacy and tolerability of neoadjuvant gemcitabine plus split-dose cisplatin in patients with localised high-grade upper tract urothelial carcinoma.

Early trial findings indicate that adding atezolizumab to neoadjuvant gemcitabine plus cisplatin might improve the outcome of patients with muscle-invasive bladder cancer scheduled to undergo radical cystectomy.

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.